Generate Biomedicines, Inc. (GENB)

Pharmaceutical Preparations · market cap $2.1B · as of 2026-07-17

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-05 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Generate Biomedicines (GENB) is a clinical-stage pharmaceutical company with a market cap of approximately $1.8B and a single disclosed pipeline asset, GB-0895, currently in Phase 3 development for severe asthma. The company carries $160.6M in cash against an estimated six-month runway, creating near-term financing pressure independent of clinical outcomes. No revenue has been reported.

The catalyst path

2026-11-05 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
GB-0895	Phase 3	Severe Asthma

Price & technical context

3-month

-20.7%

6-month

+3.7%

12-month

—

52-wk range

$11.21–$20.38

vs 50-day MA

-10.8%

vs 200-day MA

—

Realized vol

87.6%

Max drawdown

-32.3%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for GENB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.